Meril Life Sciences receives CE marking for their scaffold -MeRes100 BRS, becoming the first thin-strut bioresorbable scaffold.
Cardiovascular related diseases such as coronary artery disease are the biggest reason of mortality in India. Stents are accepted widely as a primary treatment for coronary artery disease and associated lesions or blockages due to deposition of fat and plaque formation.
MeRes100 was engineered as a solution to mend the gap between temporary treatment horizon for opening a blockage and undesirably permanent nature of a metallic DES implant.
Coverage of strut indicates healing extent; it is a crucial measure of efficacy and MeRes100 was made with a thinner strut and material which is highly biocompatible to ensure high strut coverage, which also indicates lowered risk of adverse cardiac events and also reduction in probability of repeat procedures.
First generation bioresorbable scaffolds have not demonstrated the most favourable results at long term horizons. The next generation bioresorbable scaffold with reduction in strut thickness, profile improvement for better deliverability, faster degradation and possibly lower scaffold thrombosis is a revolutionary development in interventional cardiology.
Copyright © 2019 Institute of Good Manufacturing Practices India ( IGMPI® All Rights Reserved. Trademarks are the property of the owner )